RRM1 and familial pancreatic carcinoma: Notably, PRNP showed the strongest positive correlation with RRM1 (Pearson’s R = 0.37, p < 0.05), supporting its prioritization as a potential therapeutic target for overcoming gemcitabine resistance in pancreatic cancer (Figure 2E).